NASDAQ:AXDX

Accelerate Diagnostics (AXDX) Stock Forecast, Price & News

$0.75

+0.06 (+8.70%)

(As of 06/2/2023 ET)

Compare

Today's Range: $0.70
▼
$0.75
50-Day Range: $0.50
▼
$0.90
52-Week Range: $0.45
▼
$3.74

Volume: 96,111 shs
Average Volume: 178,040 shs
Market Capitalization: $74.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Accelerate Diagnostics MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
4.07% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.62
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$123,024 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.59) to ($0.52) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

834th out of 983 stocks

Analytical Instruments Industry

21st out of 27 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Accelerate Diagnostics.

3.0

Short Interest

Percentage of Shares Shorted
4.07% of the outstanding shares of Accelerate Diagnostics have been sold short.
Short Interest Ratio / Days to Cover
Accelerate Diagnostics has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.
Change versus previous month
Short interest in Accelerate Diagnostics has recently decreased by 6.02%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Accelerate Diagnostics does not currently pay a dividend.
Dividend Growth
Accelerate Diagnostics does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Accelerate Diagnostics has received a 74.73% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" product. See details.
Environmental Sustainability
The Environmental Impact score for Accelerate Diagnostics is -1.62.

0.0

News and Social Media Coverage

Search Interest
Only 1 people have searched for AXDX on MarketBeat in the last 30 days. This is a decrease of -94% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Accelerate Diagnostics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Accelerate Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $123,024.00 in company stock.
Percentage Held by Insiders
42.20% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 33.14% of the stock of Accelerate Diagnostics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Accelerate Diagnostics are expected to grow in the coming year, from ($0.59) to ($0.52) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Accelerate Diagnostics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Accelerate Diagnostics is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Accelerate Diagnostics (NASDAQ:AXDX) Stock

Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The firm's products include Accelerate Pheno and Accelerate PhenoTest. The company was founded in 1982 and is headquartered in Tucson, AZ.

Receive AXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

AXDX Stock News Headlines

May 18, 2023 | americanbankingnews.com

Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.com

May 12, 2023 | finanznachrichten.de

Accelerate Diagnostics, Inc.: Accelerate Diagnostics Reports First Quarter 2023 Financial Results

June 3, 2023 | Legacy Research (Affiliate) (Ad)

“One-Stock Millionaire” IGNORES 99.9% of the Market

During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.

May 11, 2023 | msn.com

Recap: Accelerate Diagnostics Q1 Earnings

May 11, 2023 | finance.yahoo.com

Accelerate Diagnostics Reports First Quarter 2023 Financial Results

May 11, 2023 | finance.yahoo.com

Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement

May 10, 2023 | markets.businessinsider.com

Accelerate Diagnostics is about to announce its earnings — here's what Wall Street expects

May 9, 2023 | americanbankingnews.com

Accelerate Diagnostics (AXDX) Scheduled to Post Quarterly Earnings on Thursday

June 3, 2023 | Behind the Markets (Ad)

How A.I. Could Make Most 21st Century Diseases EXTINCT

On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...

April 27, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), SurModics (SRDX) and Accelerate Diagnostics (AXDX)

April 27, 2023 | finance.yahoo.com

Accelerate Diagnostics scheduled call to review 2023 first quarter results

April 17, 2023 | finance.yahoo.com

Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) 38% Jump Shows Its Popularity With Investors

April 4, 2023 | americanbankingnews.com

Q1 2023 EPS Estimates for Accelerate Diagnostics, Inc. Decreased by Analyst (NASDAQ:AXDX)

April 3, 2023 | finance.yahoo.com

Accelerate Diagnostics (AXDX) Upgraded to Buy: What Does It Mean for the Stock?

April 3, 2023 | americanbankingnews.com

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Short Interest Update

April 1, 2023 | finance.yahoo.com

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q4 2022 Earnings Call Transcript

March 31, 2023 | americanbankingnews.com

Accelerate Diagnostics, Inc. to Post Q1 2024 Earnings of ($0.16) Per Share, William Blair Forecasts (NASDAQ:AXDX)

March 30, 2023 | finanznachrichten.de

Accelerate Diagnostics, Inc.: Accelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results

March 30, 2023 | americanbankingnews.com

Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by StockNews.com

March 29, 2023 | msn.com

Accelerate Diagnostics (AXDX) Reports Q4 Loss, Misses Revenue Estimates

March 29, 2023 | finance.yahoo.com

Accelerate Diagnostics Reports Fourth Quarter and Full Year 2022 Financial Results

March 28, 2023 | markets.businessinsider.com

Craig-Hallum Keeps Their Hold Rating on Accelerate Diagnostics (AXDX)

March 27, 2023 | americanbankingnews.com

Accelerate Diagnostics (AXDX) to Release Earnings on Wednesday

March 15, 2023 | finance.yahoo.com

Accelerate Diagnostics scheduled call to review 2022 fourth quarter and full year results

March 8, 2023 | finance.yahoo.com

Accelerate Diagnostics announces appointment of Hany Massarany to Chairman of Board of Directors

February 19, 2023 | marketwatch.com

Allergy Diagnostics Market New Insight Report 2023: Estimated to Accelerate Industry Growth with SWOT Analysis, Top Players, and Outlook 2029

February 10, 2023 | theglobeandmail.com

Closing Bell: Accelerate Absolute Return Hdg Fund ETF flat on Friday (HDGE)

See More Headlines

AXDX Price History

30 days | 90 days | 365 days | Advanced Chart

AXDX Company Calendar

Last Earnings: 3/29/2023
Today: 6/03/2023
Next Earnings (Estimated): 8/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Analytical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:AXDX
CUSIP: N/A
CIK: 727207
Web: acceleratediagnostics.com
Phone: (520) 365-3100
Fax: 520-269-6580
Employees: 220
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.72)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-62,490,000.00
Net Margins: -516.49%
Pretax Margin: -522.81%
Return on Equity: N/A
Return on Assets: -105.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.63
Quick Ratio: 0.55

Sales & Book Value

Annual Sales: $12.75 million
Price / Sales: 5.87
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.39) per share
Price / Book: -1.92

Miscellaneous

Outstanding Shares: 99,830,000
Free Float: 57,703,000
Market Cap: $74.87 million
Optionable: Optionable
Beta: 1.19

Key Executives

Jack Phillips
President, Chief Executive Officer & Director

Maya Gowri
Head-Operations & Senior Vice President

David Patience
Chief Financial Officer

Lawrence Mertz
Chief Technology Officer

Gretchen Strohminger
Senior VP, Head-Human Resources & Culture

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AXDX Stock - Frequently Asked Questions

Should I buy or sell Accelerate Diagnostics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXDX shares.
View AXDX analyst ratings or view top-rated stocks.
How have AXDX shares performed in 2023?: Accelerate Diagnostics' stock was trading at $0.7060 at the beginning of 2023. Since then, AXDX shares have increased by 6.2% and is now trading at $0.75.
View the best growth stocks for 2023 here.
When is Accelerate Diagnostics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our AXDX earnings forecast.
How were Accelerate Diagnostics' earnings last quarter?: Accelerate Diagnostics, Inc. (NASDAQ:AXDX) posted its quarterly earnings data on Wednesday, March, 29th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.02. The medical research company had revenue of $2.97 million for the quarter, compared to analysts' expectations of $3 million.
What other stocks do shareholders of Accelerate Diagnostics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).
What is Accelerate Diagnostics' stock symbol?: Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?: Accelerate Diagnostics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Griffin Asset Management Inc. (10.29%), Tejara Capital Ltd (0.36%), Allworth Financial LP (0.15%), TCI Wealth Advisors Inc. (0.09%), Chartist Inc. CA (0.07%) and Price T Rowe Associates Inc. MD (0.06%). Insiders that own company stock include David Patience, Hany Massarany, Jack Phillips, Jack W Schuler, Larry Michael Mertz, Romney Humphries, Ron Price and Steven Reichling.
View institutional ownership trends.
How do I buy shares of Accelerate Diagnostics?: Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Accelerate Diagnostics' stock price today?: One share of AXDX stock can currently be purchased for approximately $0.75.
How much money does Accelerate Diagnostics make?: Accelerate Diagnostics (NASDAQ:AXDX) has a market capitalization of $74.87 million and generates $12.75 million in revenue each year. The medical research company earns $-62,490,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.
How many employees does Accelerate Diagnostics have?: The company employs 220 workers across the globe.
How can I contact Accelerate Diagnostics?: Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The official website for the company is acceleratediagnostics.com. The medical research company can be reached via phone at (520) 365-3100, via email at investors@axdx.com, or via fax at 520-269-6580.

This page (NASDAQ:AXDX) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial